Jean Chen, NP-C
Nurse Practitioners (Family Nurse Practitioner)
- Medicare participating
At a glance
- Years since graduation
- 13
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 86
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Nurse Practitioner primary
TX license AP126751
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Primary Health Physicians PLLC (239 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 86
- Services billed
- 252
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Injection, dexamethasone sodium phosphate, 1 mg | 100 | 16 |
| New patient office or other outpatient visit, 30-44 minutes | 34 | 34 |
| Established patient office or other outpatient visit, 30-39 minutes | 25 | 22 |
| Injection of drug or substance under skin or into muscle | 24 | 22 |
| New patient office or other outpatient visit, 45-59 minutes | 23 | 23 |
| Established patient office or other outpatient visit, 20-29 minutes | 16 | 16 |
| Detection test by immunoassay with direct visual observation for severe acute respiratory syndrome coronavirus 2 (covid-19) | 14 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Austin, TX | 36 |
| Doxycycline Hyclate Other prescribers in Austin, TX | 30 |
| Mupirocin Other prescribers in Austin, TX | 28 |
| Amoxicillin-Clavulanate Potass (amoxicillin/potassium clav) Other prescribers in Austin, TX | 25 |
| Diclofenac Sodium Other prescribers in Austin, TX | 23 |
| Paxlovid (nirmatrelvir/ritonavir) Other prescribers in Austin, TX | 19 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Austin, TX | 17 |
| Clindamycin Hcl Other prescribers in Austin, TX | 16 |
| Nitrofurantoin Mono-Macro (nitrofurantoin monohyd/m-cryst) Other prescribers in Austin, TX | 15 |
| Cyclobenzaprine Hcl Other prescribers in Austin, TX | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $47,983 in research payments for these studies, mostly to the institutions running them.
- A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
Eli Lilly and Company · Active, not recruiting · NCT05556512 - A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
Eli Lilly and Company · Completed · NCT05803421 - A phase 2, randomized, open-label, comparator-controlled trial to evaluate the efficacy and safety of LY3938577 in study participants, with type 2 diabetes mellitus previously treated with basal insulin
Eli Lilly and Company - Senseonics CTP-0039
Senseonics, Incorporated
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.